Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

BioPharma « Terug naar discussie overzicht

GTCB los ?

27.049 Posts, Pagina: « 1 2 3 4 5 6 ... 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 ... 1349 1350 1351 1352 1353 » | Laatste

Omlaag ↓

[verwijderd] 23 februari 2006 12:50

Analisten voor zo'n klein bedrijfje ? Laat me niet lachen, ze hebben in de states honderduizenden andere bedrijven te coveren. als ze boven de 5 of 10 dollar komen en een steady revenue hebben, dan misschien ja. Ik ken niet veel analisten die prijzen plakken op een puur research bedrijfje ook, veel te gevaarlijk.

quote:
Henk Snaph schreef:
[quote=Tweeke]
[quote=arend007]
De berichttgeving hier is prima, maar heb wel 1 vraag. Waarom staat er geen nieuws op Nasdaq of Wallstreet of andere sites. Er is totaal geen nieuws te vinden met onderbouwing van GTCB.
[/quote]
Dat is niet vreemd. Alles wat je nu hoort IS geen nieuws, heeft allang eerder in persberichten en interviews gestaan.
Voor het grote publiek is het nieuw ja.
Je hoeft van GTCB niet te verwachten dat ze in een persbericht melden op welke zenders ze te zien zijn en hoe laat.

[/quote]

Wat mij echter wel bevreemd is dat er zich nog steeds geen analisten melden!

Henks

[verwijderd] 23 februari 2006 12:54

Ik hoop alleen wel dat ze voorbeurs komen, maar waarschijnlijk niet. Dus kunnen ze natuurlijk nog ongelooflijk hard gaan shuffelen na opening. Dan kan je ze pas echt bang maken!!

Groet,

IM.

[verwijderd] 23 februari 2006 13:05

quote:
PRVIEW schreef:
nog 3 uurtjes en we weten meer !!!

tik tak tik tak...gaat de tijd langzamer vandaag, of ligt dat aan mij.

Ik begin nu toch bijna nerveus te worden. :-)

[verwijderd] 23 februari 2006 13:07

news.bbc.co.uk/nolavconsole/ukfs_news...

[verwijderd] 23 februari 2006 13:19

quote:
Elbee schreef:
[quote=PRVIEW]
nog 3 uurtjes en we weten meer !!!
[/quote]

tik tak tik tak...gaat de tijd langzamer vandaag, of ligt dat aan mij.

Ik begin nu toch bijna nerveus te worden. :-)

Geen enkele reden om nerveus te worden. Wij kunnen, net zomin GTCB trouwens, iets aan de uitslag veranderen. Tot en met gisteren zijn posities ingenomen op, naar ik hoop, rationele gronden. Vandaag moet pay day worden na al het intensieve werk.

groet,

Schouterman

[verwijderd] 23 februari 2006 13:23

Pay daY?

Ik ben er nog niet zo zeker van, maar laat maar komen !!

Nog 2 uurtjes te gaan...

[verwijderd] 23 februari 2006 13:35

GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)
Thursday February 23, 7:34 am ET

ludwig mack 23 februari 2006 13:35

quote:
Schouterman schreef:
[quote=Elbee]
[quote=PRVIEW]
nog 3 uurtjes en we weten meer !!!
[/quote]

tik tak tik tak...gaat de tijd langzamer vandaag, of ligt dat aan mij.

Ik begin nu toch bijna nerveus te worden. :-)
[/quote]

Geen enkele reden om nerveus te worden. Wij kunnen, net zomin GTCB trouwens, iets aan de uitslag veranderen. Tot en met gisteren zijn posities ingenomen op, naar ik hoop, rationele gronden. Vandaag moet pay day worden na al het intensieve werk.

groet,

Schouterman

ik hoop dat je genoeg cash hebt schouterman, want je wilde bij goedkeuring toch bijkopen :)

positivo73 23 februari 2006 13:37

quote:
gismo74 schreef:
GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)
Thursday February 23, 7:34 am ET

???

[verwijderd] 23 februari 2006 13:37

GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)

E-mail | Print | | Disable live quotes Last Update: 7:34 AM ET Feb 23, 2006

FRAMINGHAM, Mass., Feb 23, 2006 (BUSINESS WIRE) -- GTC Biotherapeutics, Inc. (GTCB : gtc biotherapeutics inc com
News , chart, profile, more
Last: 2.25+0.05+2.27%

7:00am 02/23/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GTCB2.25, +0.05, +2.3%) announced today that it has been told that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) intends to issue a negative opinion on the market authorization application (MAA) for ATryn(R), GTC's recombinant form of human antithrombin. On the basis of recent conversations, GTC understands that the CHMP, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval. In addition, GTC understands that the CHMP has concerns about sufficient immunologic data and the lack of clinical data from ATryn(R) produced with an additional filtration step. GTC intends to take advantage of the appeal process to request a CHMP re-examination of GTC's submission.
GTC's European development and commercialization partner, LEO Pharma A/S, has affirmed that they remain committed to their collaboration with GTC and will continue to pursue the primary goal of development of an acquired deficiency indication for Europe. Acquired deficiency indications represent the most significant market opportunity for the product. GTC and LEO entered into a collaborative development and commercialization agreement for ATryn(R) in Europe, Canada, and the Middle East in November 2005. GTC is also continuing a multinational study of ATryn(R) in hereditary antithrombin deficient patients in preparation for submission of a Biologics License Application (BLA) in the U.S. Enrollment is planned to be completed in 2006 and a BLA submitted in the first half of 2007.
"Although we are very disappointed with the late-breaking concerns on the clinical data and the negative opinion, we are pleased by the commitment of LEO Pharma to continue working on further development of this important product in Europe in acquired antithrombin deficiency," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "In addition we remain committed to completing our submission for BLA approval in the US. The US remains a major long term opportunity for ATryn(R) in a range of hereditary and acquired deficiency indications. It is also important for our transgenic technology platform that the CHMP has not identified to us any significant outstanding issues related to the manufacturing and production control systems for ATryn(R)."
Antithrombin is a protein in human plasma that has anticoagulant and anti-inflammatory properties. Patients that have a hereditary deficiency indication are prone to developing blood clots during high-risk procedures, such as surgery and childbirth. Providing supplemental antithrombin during these procedures may prevent the occurrence of DVT's and other thromboembolic events. Antithrombin supplementation therapy may also be useful in the treatment of patients who acquire temporary antithrombin deficiency during certain clinical situations such as burns, coronary artery bypass surgery, disseminated intravascular coagulation, sepsis, and bone marrow transplant.
Conference Call Information
GTC will discuss this opinion and the status of ATryn(R) in a web cast conference call at 9:00 a.m. (Eastern) today. The web cast may be heard through GTC's web site at www.gtc-bio.com. The dial-in number from inside the United States is 1-800-901-5231. The dial-in number from outside the United States is 1-617-786-2961. The participant passcode is 41916712.
About GTC Biotherapeutics, Inc.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. In addition to the ATryn(R) program, GTC is developing recombinant human alpha-1 antitrypsin, recombinant human albumin, a CD137 antibody as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding its expectations for the final CHMP opinion, the development of an acquired deficiency indication with LEO, the ongoing phase III study and preparation of a BLA, and GTC's request for a CHMP re-examination of the submission. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with regulatory approval and the actions of partners. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
SOURCE: GTC Biotherapeutics, Inc.
GTC Biotherapeutics, Inc. Thomas E. Newberry, 508-370-5374 or Feinstein Kean Healthcare for GTC Biotherapeutics, Inc. Francesca DeVellis, 617-577-8110 Copyright Business Wire 2006 ********************************************************************** As of Sunday, 02-19-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 11-03-2005 for GTCB @ $1.71. (C) 2006 Comtex News Network, Inc. All rights reserved.

E-mail | Print | | Disable live quotes 6:40AM 2/23/2006Stock futures search for catalyst after Wednesday rise
5:58AM 2/23/2006Toll Brothers earnings rise 49%, top forecast
5:51AM 2/23/2006Reuters shares tumble on outlook concerns
5:09AM 2/23/2006Utilities spark European gains
8:00PM 2/22/2006Government solicits bids on nuclear disaster drugs
More newsSponsored Links
Get listed hereBuy Stocks Online at Scottrade
$7 stock trades at Scottrade. No account inactivity or maintenance fees. Open an account for $500. Apply today.
www.scottrade.com

Tomorrow's Hot Stock Pick
Free reports, picks, and tips on potentially huge winners. Penny stocks, undervalued, and undiscovered situations. Unique ideas to make money now.
www.RocketStockPicks.com

15 Energy Stocks to Sell Now
Natural gas prices top $20! Free report reveals the truth about this crisis and how you can profit. 15 big-name losers to avoid. The case for $100 oil. And more – all free.
www.changewave.com

ludwig mack 23 februari 2006 13:37

quote:
gismo74 schreef:
GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)
Thursday February 23, 7:34 am ET

zonder bron ....

[verwijderd] 23 februari 2006 13:39

www.marketwatch.com/News/Story/Story....

[verwijderd] 23 februari 2006 13:40

Lekker ,kunnen we in de voorbeurshandel ons geld zien verdwijnen.

spyfly 23 februari 2006 13:41

hmm, idd bagger! maar ze 'verwachten'...beetje vaag!

positivo73 23 februari 2006 13:41

Mijn Engels is slecht. Is het afgekeurd?

[verwijderd] 23 februari 2006 13:42

zuur!

[verwijderd] 23 februari 2006 13:42

ziet er niet goed uit

[verwijderd] 23 februari 2006 13:42

Over en sluiten - dat wordt een gigantische dump in de opening

[verwijderd] 23 februari 2006 13:43

Zo ben ik blij dat ik gisteren de gok heb gemaakt te verkopen, het is ook altijd wat bij gtcb. Je wordt er moe van. Ik geloof er niet meer in.

positivo73 23 februari 2006 13:43

Is er definitieve afkeuring of uitstel dan?

27.049 Posts, Pagina: « 1 2 3 4 5 6 ... 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 ... 1349 1350 1351 1352 1353 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Direct naar Forum

Markt vandaag

AEX	916,04	+0,83	+0,09%	18:05
AMX	938,72	+0,55	+0,06%	18:05
ASCX	1.260,53	+13,11	+1,05%	18:05
BEL 20	3.984,87	+14,95	+0,38%	18:05
Germany40^	18.788,30	+94,93	+0,51%	21:13
US30^	39.113,30	+35,00	+0,09%	21:13
US500^	5.315,31	+8,67	+0,16%	21:11
Nasd100^	18.878,30	+64,20	+0,34%	21:14
Japan225^	38.955,20	+141,20	+0,36%	19:36
WTI	78,53	+0,81	+1,04%	20:29
Brent	82,80	+0,99	+1,21%	18:59
EUR/USD	1,0859	+0,0013	+0,12%	21:15
BTC/USD	69.846,23	+1.000,29	+1,45%	21:14
Gold spot	2.351,00	+17,00	+0,73%	21:02